RTW Biotech's portfolio firm Penumbra acquired by Boston Scientific
(Alliance News) - RTW Biotech Opportunities Ltd on Thursday noted Boston Scientific Corp's USD14.5 billion acquisition of Penumbra Inc, a portfolio company that represented 1.0% of its net asset value at the end of 2025. Read More